(P 333) METABOLIC SYNDROME CORRELATION WITH LIPOSARCOMA INCIDENCE AND OUTCOMES: A RETROSPECTIVE ANALYSIS.

Objective: Metabolic syndrome (MS) has been linked to the development of various cancers, but its association with liposarcoma (LPS) remains unexplored.

Methods: We conducted an IRB-approved, retrospective study to investigate the influence of MS and its components in LPS patients at the Sylvester Comprehensive Cancer Center. Medical records of LPS patients between January 2015 and June 2024 were reviewed. MS was defined as either a documented history of MS or the presence of at least three of the following four components: diabetes mellitus (DM), hypertension (HTN), hyperlipidemia (HLD), or obesity. Demographic, MS components and LPS data was collected. The percentage of MS in LPS patients was compared to the incidence in general population. Logistic regression analysis was used to assess the odds ratio (OR) of disease progression with different components of MS. Additionally, Cox proportional hazard ratio (HR) was calculated to assess the impact of MS and BMI on survival outcomes.

Results: Of the 132 LPS patients, 58% were male, and 34.5% were Hispanic, with a mean age of 64.5 years (Standard Deviation (SD) = 13.79), with the majority being White (83.2%). Subtypes included 46.2% dedifferentiated, 19.3% well-differentiated, 13% pleomorphic, and the remaining cases were myxoid and round cell pathology. Most tumors were axial (63.6%), and 41.2% of cases were Stage 3. Disease progression despite treatment and distant metastasis were observed in around one-third of patients, 34.5% and 35.3%, respectively. The overall mortality rate was 21%.
HTN, DM, and HLD were prevalent in the cohort at 62.2%, 22,7%, and 57%, respectively. MS was present in 61.3% cases. BMI greater than 25 in 75.6% of patients with a mean BMI of 29.1 (SD = 5.6; 95% Confidence Interval (95CI) = 28.1-30.2). A significant proportion of people used HLD and DM medications, including 51.3% on statins and 17.6% on metformin. The Relative Incidence of MS was 1.5 (p < 0.001) in LPS patients compared to the general population. DM was associated with progressive disease with OR of 3.01 (95CI= 1.5-7.4), while obesity was associated with decreased risk of adverse outcomes (Table). No specific genetic variant was observed in LPS patients with MS.

Conclusion: Our study raises concern that individuals with MS may be at a higher risk of LPS. DM’s association with disease progression might be related to insulin resistance. Decreased mortality with obesity might be secondary to better treatment tolerance.

Impact of Metabolic Syndrome Components on Liposarcoma Progression and Survival